Inhalation of glycopyrronium inhibits cigarette smoke-induced acute lung inflammation in a murine model of COPD

International Immunopharmacology

Volumn 18, Issue 2, 2014, Pages 358-364

  Shen, Liang Liang ^a,b   Liu, Ya Nan ^a,b   Shen, Hui Juan ^b   Wen, Chong ^c   Jia, Yong Liang ^b   Dong, Xin Wei ^b   Jin, Fang ^c   Chen, Xiao Ping ^d   Sun, Yun ^a   Xie, Qiang Min ^b,e  

^a YANGZHOU UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY   (China)

^d Jiashilianbo Medicine Science and Technique Co   (China)

^e ZHEJIANG UNIVERSITY   (China)

Author keywords

Airway inflammation; Cigarette smoke; COPD; Drug delivery; Glycopyrronium bromide; Muscarinic receptor antagonist

Indexed keywords

CIGARETTE SMOKE; GELATINASE B; GLUTATHIONE; GLYCOPYRRONIUM BROMIDE; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LUNG LAVAGE; LUNG PARENCHYMA; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AIRWAY INFLAMMATION; CIGARETTE SMOKE; COPD; DRUG DELIVERY; GLYCOPYRRONIUM BROMIDE; MUSCARINIC RECEPTOR ANTAGONIST;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GLYCOPYRROLATE; LYMPHOCYTES; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED ICR; MUSCARINIC ANTAGONISTS; NEUTROPHILS; OXIDATIVE STRESS; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TOBACCO;

EID: 84892692126     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.12.021     Document Type: Article

References (41)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management and Prevention of COPD Available rom: http://www.goldcopd.org/ 2013
2. S. Sethi, D.A. Mahler, P. Marcus, C.A. Owen, B. Yawn, and S. Rennard Inflammation in COPD: implications for management Am J Med 125 2012 1162 1170
3. L. Taraseviciene-Stewart, and N.F. Voelkel Molecular pathogenesis of emphysema J Clin Invest 118 2008 394 402
4. R.M. Tuder, and I. Petrache Pathogenesis of chronic obstructive pulmonary disease J Clin Invest 122 2012 2749 2755
5. T. Yoshida, and R.M. Tuder Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease Physiol Rev 87 2007 1047 1082
6. W. MacNee Oxidative stress and lung inflammation in airways disease Eur J Pharmacol 429 2001 195 207
7. I. Rahman, S.K. Biswas, and A. Kode Oxidant and antioxidant balance in the airways and airway diseases Eur J Pharmacol 533 2006 222 239
8. I.M. Adcock, and P.J. Barnes Molecular mechanisms of corticosteroid resistance Chest 134 2008 394 401
9. K.M. Beeh, D. Singh, L. Di Scala, and A. Drollmann Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial Int J Chron Obstruct Pulmon Dis 7 2012 503 513
10. A. D'Urzo, G.T. Ferguson, J.A. van Noord, K. Hirata, C. Martin, and R. Horton et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial Respir Res 12 2011 156
11. E. Kerwin, J. Hebert, N. Gallagher, C. Martin, T. Overend, and V.K. Alagappan et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Eur Respir J 40 2012 1106 1114
12. T. Ali-Melkkila, J. Kanto, and E. Iisalo Pharmacokinetics and related pharmacodynamics of anticholinergic drugs Acta Anaesthesiol Scand 37 1993 633 642
13. C. Vogelmeier, and D. Banerji NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease Ther Adv Respir Dis 5 2011 163 173
14. K.M. Beeh, T. Welte, and R. Buhl Anticholinergics in the treatment of chronic obstructive pulmonary disease Respiration 69 2002 372 379
15. D.A. Sykes, M.R. Dowling, J. Leighton-Davies, T.C. Kent, L. Fawcett, and E. Renard et al. The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium J Pharmacol Exp Ther 343 2012 520 528
16. R. Sechaud, D. Renard, L. Zhang-Auberson, L. Motte Sde, A. Drollmann, and G. Kaiser Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD) Int J Clin Pharmacol Ther 50 2012 118 128
17. F.F. Li, J. Shen, H.J. Shen, X. Zhang, R. Cao, and Y. Zhang et al. Shp2 plays an important role in acute cigarette smoke-mediated lung inflammation J Immunol 189 2012 3159 3167
18. M.J. Bao, J. Shen, Y.L. Jia, F.F. Li, W.J. Ma, and H.J. Shen et al. Apple polyphenol protects against cigarette smoke-induced acute lung injury Nutrition 29 2013 235 243
19. Y. Guan, F.F. Li, L. Hong, X.F. Yan, G.L. Tan, and J.S. He et al. Protective effects of liquiritin apioside on cigarette smoke-induced lung epithelial cell injury Fundam Clin Pharmacol 26 2012 473 483
20. F. Tietze Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues Anal Biochem 27 1969 502 522
21. C.R. Gwilt, L.E. Donnelly, and D.F. Rogers The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation? Pharmacol Ther 115 2007 208 222
22. K. Kawashima, and T. Fujii Extraneuronal cholinergic system in lymphocytes Pharmacol Ther 86 2000 29 48
23. B.J. Proskocil, H.S. Sekhon, Y. Jia, V. Savchenko, R.D. Blakely, and J. Lindstrom et al. Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells Endocrinology 145 2004 2498 2506
24. Y. Wang, E.F. Pereira, A.D. Maus, N.S. Ostlie, D. Navaneetham, and S. Lei et al. Human bronchial epithelial and endothelial cells express alpha7 nicotinic acetylcholine receptors Mol Pharmacol 60 2001 1201 1209
25. R. Gosens, J. Zaagsma, M. Grootte Bromhaar, A. Nelemans, and H. Meurs Acetylcholine: a novel regulator of airway smooth muscle remodelling? Eur J Pharmacol 500 2004 193 201
26. I. Wessler, and C.J. Kirkpatrick Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans Br J Pharmacol 154 2008 1558 1571
27. P. Casarosa, T. Bouyssou, S. Germeyer, A. Schnapp, F. Gantner, and M. Pieper Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs J Pharmacol Exp Ther 330 2009 660 668
28. G. Villetti, M. Bergamaschi, F. Bassani, P.T. Bolzoni, S. Harrison, and P.M. Gigli et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways Br J Pharmacol 148 2006 291 298
29. A. Pahl, A. Bauhofer, U. Petzold, P.J. Cnota, J. Maus, and K. Brune et al. Synergistic effects of the anti-cholinergic R, R-glycopyrrolate with anti-inflammatory drugs Biochem Pharmacol 72 2006 1690 1696
30. A. Churg, M. Cosio, and J.L. Wright Mechanisms of cigarette smoke-induced COPD: insights from animal models Am J Physiol Lung Cell Mol Physiol 294 2008 L612 L631
31. K. Blidberg, L. Palmberg, B. Dahlén, A.S. Lantz, and K. Larsson Chemokine release by neutrophils in chronic obstructive pulmonary disease Innate Immun 18 3 2012 503 510
32. S.F. Liu, C.C. Wang, W.F. Fang, Y.C. Chen, and M.C. Lin MCP1-2518 polymorphism and chronic obstructive pulmonary disease in Taiwanese men Exp Lung Res 36 5 2010 277 283
33. N.S. Pauwels, K.R. Bracke, L.L. Dupont, G.R. Van Pottelberge, S. Provoost, and T. Vanden Berghe et al. Role of IL-1alpha and the Nlrp3/caspase-1/IL-1beta axis in cigarette smoke-induced pulmonary inflammation and COPD Eur Respir J 38 2011 1019 1028
34. S.E. Tanni, N.R. Pelegrino, A.Y. Angeleli, C. Correa, and I. Godoy Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients J Inflamm (Lond) 7 2010 29
35. P.J. Barnes Alveolar macrophages as orchestrators of COPD COPD 1 2004 59 70
36. G.K. Griffin, G. Newton, M.L. Tarrio, D.X. Bu, E. Maganto-Garcia, and V. Azcutia et al. IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation J Immunol 188 2012 6287 6299
37. I. Rahman, and I.M. Adcock Oxidative stress and redox regulation of lung inflammation in COPD Eur Respir J 28 2006 219 242
38. I. Rahman, and W. MacNee Lung glutathione and oxidative stress: implications in cigarette smoke-induced airway disease Am J Physiol 277 1999 L1067 L1088
39. V. Lagent, and E. Boichot Role of matrix metalloproteinases in the inflammatory process of respiratory diseases J Mol Cell Cardiol 48 2010 440 444
40. M.M. Gueders, J.M. Foidart, A. Noel, and D.D. Cataldo Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases Eur J Pharmacol 533 2006 133 144
41. P.K. Srivastava, S.G. Dastidar, and A. Ray Chronic obstructive pulmonary disease: role of matrix metalloproteases and future challenges of drug therapy Expert Opin Investig Drugs 16 2007 1069 1078